Stock Market Reviews

DYAI (Dyadic International, Inc.) News

Get the latest news, insights, and market updates on DYAI (Dyadic International, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
  Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relationsAdvanced multiple recombinant protein programs toward commercializationAchieved key development and commercial milestones across life sciences and nutrition marketsFirst purchase order received in cell culture media and molecular biology reagent segmentsSecured ERS Genomics CRISPR license to optimize productio
  Nov 12, 2025 - $DYAI
• ERS Genomics and Dyadic Applied BioSolutions Sign CRISPR/Cas9 License Agreement
  ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced they have signed a non-exclusive agreement granting access to ERS' foundational CRISPR/Cas9 patent portfolio.
  Nov 10, 2025 - $DYAI
• Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics
  JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced a CRISPR/Cas9 license agreement. This agreement grants Dyadic access to ERS’ CRISPR/Cas9 patent portfolio, enhancing Dyadic’s ability to accelerate strain engineering and pathway optimization to enh
  Nov 10, 2025 - $DYAI
• How Analyst Views on Dyadic International Are Shifting With New Commercialization and Partnership Risks
  Dyadic International's fair value estimate has held steady at $5.67 per share, even as the discount rate has risen slightly from 7.04% to 7.20%. This adjustment reflects a blend of optimism about upcoming product commercialization and healthy revenue projections, balanced against the cautious outlook on execution risks and reliance on external partners. Stay tuned to find out how investors can track these ongoing developments and stay informed about the shifting narrative surrounding Dyadic's...
  Nov 8, 2025 - $DYAI
• Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025
  JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results
  Oct 29, 2025 - $DYAI
• What Recent Analyst Revisions Mean for the Evolving Story Behind Dyadic International
  Dyadic International's consensus analyst price target has recently been revised downward from $7.00 to $5.67 per share, reflecting a reassessment of the company's outlook. This change follows a modest increase in the discount rate from 6.94% to 7.04% as well as a significant reduction in revenue growth projections. As analysts weigh the latest mix of opportunities and risks, readers are encouraged to stay tuned for ways to monitor these evolving expectations and the company's ongoing...
  Oct 24, 2025 - $DYAI
• Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments
  JUPITER, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced the achievement of additional milestone payments in its collaborations with Proliant Health & Biologicals in life sciences and Inzymes ApS in food and nutrition, along with upd
  Oct 6, 2025 - $DYAI
• Craig Hallum Bullish on Dyadic International, Inc. (DYAI) With $5 Target
  Dyadic International, Inc. (NASDAQ:DYAI) is among the best fundamentally strong penny stocks to buy right now. Analysts at Craig-Hallum have started coverage on Dyadic International, Inc. (NASDAQ:DYAI) with a ‘Buy’ rating and a price target of $5.00, reflecting an upside potential of nearly 405.7%. The research firm highlights the company’s strategic focus on commercializing its […]
  Sep 21, 2025 - $DYAI
• Sidoti Events, LLC's Virtual September Small-Cap Conference
  NEW YORK, NY / ACCESS Newswire / September 16, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day September Small-Cap Conference taking place Wednesday and Thursday, ...
  Sep 16, 2025 - $DYAI
• Dyadic to Present at Investor Conferences and BPI East
  JUPITER, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for non-therapeutic applications in life sciences, food and nutrition, and industrial biotechnology utilizing its proprietary gene expression platforms, today announced that Joe Hazelton, Dyadic’s
  Sep 4, 2025 - $DYAI